L. Fumagalli

PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

Background First-line treatment options are limited for patients with advanced cholangiocarcinoma (CCA). Genetic alterations in the fibroblast growth factor receptor (FG...

Teresa Macarulla , MD, PhD;

Sudipta Roychowdhury , MD;

R. Shroff ;

J. Soto ;

G. Pedrioli ;

L. Fumagalli ;

C. dambkowski ;

M. Javle ;

Ghassan Abou-Alfa , MD, MBA;

D. Oh ;

I. Borbath ;

Lovely Goyal ;

Angela Lamarca , MD, PhD, MSc;

06/27/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

L. Fumagalli

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products